The Phase I Study of HS-10509 in Chinese Adult Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

May 31, 2024

Study Completion Date

October 31, 2024

Conditions
Schizophrenia
Interventions
DRUG

HS-10509

"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."

DRUG

Placebo

"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY